Literature DB >> 7547220

Haemoccult test properties according to type and number of positive slides in mass screening for colorectal cancer.

G Launoy1, C Herbert, J M Reaud, Y Thezee, J Tichet, J Maurel, V Ollivier, L Pegulu, E Caces, A Valla.   

Abstract

Despite encouraging results from recent studies, there is still no consensus to undertake mass screening using the Haemoccult test in the general population. The success of mass screening for colorectal cancer depends among other things on Haemoccult test properties. In on-going screening programmes, the Haemoccult test consists of six slides and a test is considered positive if at least one slide is coloured. The aim of this work was to study the influence of the type and number of positive slides on the Haemoccult test's positive predictive value and characteristics of screened lesions. This work focuses on 63,958 first tests in a mass screening programme in Calvados (France) among people aged 45-74 years. There was a linear relation between the positive predictive value for cancer or an adenoma larger than 1 cm and the number of positive slides (P < 10(-4)). The positive predictive value for cancer or large adenoma was significantly higher when 4-6 slides were positive (44.3%) than when only 1-3 were positive (19.1%) (P < 10(-4)). In this latter group, the subjects in whom tumours were detected were younger and had significantly less extensive cancers. Borderline tests (no slides positive and at least one slide with a blue coloration confined to the edges) had a positive predictive value for cancer or an adenoma larger than 1 cm no different to that of tests with 1-3 positive slides. Subjects with borderline results were markedly younger than the others and had less extensive cancers and rectal localisation more often than the others. Our results suggest that (1) increasing the number of positive slides required to declare a test positive leads to an increase in the positive predictive value but is not to be recommended because of the sensitivity of the test and (2) considering borderline Haemoccult tests as positive in on-going and future mass screening campaigns would allow an increase in the sensitivity of the test, especially for rectal cancer and low extensive tumours without any decrease in its positive predictive value.

Entities:  

Mesh:

Year:  1995        PMID: 7547220      PMCID: PMC2034039          DOI: 10.1038/bjc.1995.459

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Is dietary restriction always necessary in Haemoccult screening for colorectal neoplasia?

Authors:  M H Robinson; W M Thomas; G Pye; J D Hardcastle; C M Mangham
Journal:  Eur J Surg Oncol       Date:  1993-12       Impact factor: 4.424

2.  Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects.

Authors:  J D Hardcastle; W M Thomas; J Chamberlain; G Pye; J Sheffield; P D James; T W Balfour; S S Amar; N C Armitage; S M Moss
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

3.  The earlier detection of colorectal cancers: a preliminary report of the results of the Occult Blood Study.

Authors:  V A Gilbertsen; R McHugh; L Schuman; S E Williams
Journal:  Cancer       Date:  1980-06-01       Impact factor: 6.860

4.  Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; M Bradley; D C Snover; T R Church; S Williams; G Watt; L M Schuman; F Ederer; V Gilbertsen
Journal:  Gastroenterology       Date:  1989-09       Impact factor: 22.682

5.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

6.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.

Authors:  J V Selby; G D Friedman; C P Quesenberry; N S Weiss
Journal:  N Engl J Med       Date:  1992-03-05       Impact factor: 91.245

7.  [Preliminary results of a mass screening program for colorectal cancer].

Authors:  L Bedenne; G Durand; J Faivre; C Milan; M C Boutron; P Arveux; P Colombier; C Klepping
Journal:  Gastroenterol Clin Biol       Date:  1990

8.  Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark.

Authors:  O Kronborg; C Fenger; J Olsen; K Bech; O Søndergaard
Journal:  Scand J Gastroenterol       Date:  1989-06       Impact factor: 2.423

9.  Interval cancers in screening with fecal occult blood test for colorectal cancer.

Authors:  B M Jensen; O Kronborg; C Fenger
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

Review 10.  Occult blood screening for colorectal carcinoma: a critical review.

Authors:  J B Simon
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

  10 in total
  1 in total

1.  Colorectal cancer after a negative Haemoccult II test and programme sensitivity after a first round of screening: the experience of the Department of Calvados (France).

Authors:  V Bouvier; G Launoy; C Herbert; H Lefevre; J Maurel; M Gignoux
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.